Form 4: Oric Pharmaceuticals CFO Sells 20,000 Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, sold 20,000 shares of common stock for approximately $10.05 per share as part of a pre-scheduled Rule 10b5-1 trading plan.
Summary
- Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (ORIC), reported a sale of common stock.
- On July 1, 2025, Mr. Piscitelli disposed of 20,000 shares of Oric Pharmaceuticals common stock.
- The shares were sold at a weighted average price of $10.0486 per share, with prices ranging from $10.00 to $10.135.
- Following this transaction, Mr. Piscitelli directly beneficially owns 48,317 shares of Oric Pharmaceuticals common stock.
- The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Piscitelli on December 30, 2024.
Sentiment
Score: 5
Explanation: Neutral. While an insider sale can sometimes be viewed negatively, the disclosure that it was part of a pre-arranged 10b5-1 plan mitigates concerns that it signals a lack of confidence in the company's future. It's a planned liquidity event.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on new, non-public information.
Negatives
- An insider sale, even if pre-planned, reduces the direct ownership stake of a key executive in the company.
Future Outlook
Not applicable. This document is a Form 4 filing reporting an insider stock transaction and does not contain forward-looking statements or guidance.
Industry Context
This is a routine insider transaction filing and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: The sale by a CFO might be viewed with slight caution, but the 10b5-1 plan context reduces negative implications. It represents a minor reduction in insider ownership.
Key Dates
| Date | Description |
|---|---|
| 2024-12-30 | Date Rule 10b5-1 trading plan was adopted by Dominic Piscitelli. |
| 2025-07-01 | Date of transaction where Dominic Piscitelli sold 20,000 shares of common stock. |
| 2025-07-02 | Date the Form 4 was signed by Christian Kuhlen, attorney-in-fact for Dominic Piscitelli. |
Recommendation
holdKeywords
Oric Pharmaceuticals, ORIC, Dominic Piscitelli, Chief Financial Officer, CFO, Insider Sale, Form 4, SEC Filing, Stock Transaction, Rule 10b5-1, Equity Sales
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.